In Supreme Court, biosimilars industry briefs against more exclusivity

23 February 2017

An industry trade group representing manufacturers of generic and biosimilar products has urged the US Supreme Court not to grant biotech firms an extra six months of patent exclusivity.

The amicus brief was filed ahead of oral arguments, due on 26 April, in the ongoing case between Novartis (NOVN: VX) subsidiary Sandoz and US biologics maker Amgen (Nasdaq: AMGN).

The dispute centers around a lower court’s decision to block the former from selling its biosimilar version of Amgen’s $1-billion-a-year hematology product Neupogen (filgrastim) for six months, due to a clause in the Biologics Price Competition and Innovation Act (BPCIA).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK